EUVIMEDEUVIMED entdecken
Crossref

Safety and Efficacy of Apixaban Therapy for Coronary Artery Aneurysms After Kawasaki Disease

Annette L Baker iD, Kimberlee Gauvreau iD, Francesca Sperotto iD, Amy Hellinger iD, Ryan J Williams, Sarah D de Ferranti iD, Audrey Dionne iD, Kevin G Friedman iD, MaryBeth F Son iD, Paul Esteso iD, Thomas J Giorgio, Veronique C Wright iD und 3 weitere

Journal of the American Heart Association · 12.11.2026

DOI: 10.1161/jaha.126.049822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, online erschienen am 12.11.2026. Verfasst von Annette L Baker und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Boston Children's Hospital Boston MA USA. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anticoagulation combined with aspirin lowers the risk of coronary thrombosis in patients with large/giant coronary artery aneurysms following Kawasaki disease. We aimed to evaluate the safety and efficacy of apixaban in this high‐risk pediatric population and compare it to conventional anticoagulant therapy.

Methods

In this retrospective study, we described our experience with the use of apixaban in patients with Kawasaki disease with large/giant coronary artery aneurysms. In patients who were previously exposed to conventional anticoagulation, we compared rates of new coronary thrombosis or myocardial infarction (effectiveness) and clinically relevant bleeding (safety) during apixaban versus antecedent conventional therapy. All patients received concomitant antiplatelet agents. Apixaban dosing was guided by weight and anti‐Xa chromogenic assays.

Results

Between 2018 and 2025, 28 patients with Kawasaki disease (median age 6.7 years; 75% male) with large/giant coronary artery aneurysms were prescribed apixaban. Of these, 27 (96%) had previously received vitamin K antagonists or low molecular weight heparin. The rates of new coronary thrombosis and new myocardial infarctions were not higher when patients received apixaban versus conventional anticoagulation (0.025 versus 0.041 events per person‐year; incidence rate ratio [IRR], 0.61 [95% CI, 0.06–3.3] and 0.013 versus 0.041 events per person‐year; IRR, 0.31 [95% CI, 0.01–2.5], respectively). Rates of clinically relevant bleeding were also not higher for apixaban versus conventional therapy (0.038 versus 0.058 events per person‐year, IRR, 0.66 [95% CI, 0.11–2.5]).

Conclusions

In this retrospective single‐center series of pediatric patients with Kawasaki disease with large/giant coronary artery aneurysms, apixaban combined with antiplatelet therapy was well tolerated and demonstrated no evidence of increased harm relative to conventional anticoagulants. Multicenter research is needed to confirm these findings and define the optimal therapeutic range for apixaban in this high‐risk population.

Schlagwörter

Stichwörter der Autor:innen

DOACKawasaki diseaseanticoagulationapixabancoronary aneurysms

Autor:innen und Institutionen

  • Department of Cardiology Boston Children's Hospital Boston MA USA.
  • Department of Pediatrics Harvard Medical School Boston MA USA.
  • Division of Immunology Boston Children's Hospital Boston MA USA.

ORCID-Profile: Annette L Baker, Kimberlee Gauvreau, Francesca Sperotto, Amy Hellinger, Sarah D de Ferranti, Audrey Dionne, Kevin G Friedman, MaryBeth F Son, Paul Esteso, Veronique C Wright, Sunil J Ghelani, Jane W Newburger

Zitieren

APA

Baker, A. L., Gauvreau, K., Sperotto, F., Hellinger, A., Williams, R. J., de Ferranti, S. D., Dionne, A., Friedman, K. G., Son, M. F., Esteso, P., Giorgio, T. J., Wright, V. C., Ghelani, S. J., VanderPluym, C. J., & Newburger, J. W. (2026). Safety and Efficacy of Apixaban Therapy for Coronary Artery Aneurysms After Kawasaki Disease. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.049822

Vancouver

Baker AL, Gauvreau K, Sperotto F, Hellinger A, Williams RJ, de Ferranti SD, et al. Safety and Efficacy of Apixaban Therapy for Coronary Artery Aneurysms After Kawasaki Disease. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.049822

BibTeX
@article{Baker2026,
  author = {Baker, Annette L and Gauvreau, Kimberlee and Sperotto, Francesca and Hellinger, Amy and Williams, Ryan J and de Ferranti, Sarah D and Dionne, Audrey and Friedman, Kevin G and Son, MaryBeth F and Esteso, Paul and Giorgio, Thomas J and Wright, Veronique C and Ghelani, Sunil J and VanderPluym, Christina J and Newburger, Jane W},
  title = {Safety and Efficacy of Apixaban Therapy for Coronary Artery Aneurysms After Kawasaki Disease},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.126.049822}
}
Kostenlos starten →